|
|
Gilead Sciences Inc (GILD) |
|
|
|
| |
GILD's Operating Income Growth by Quarter and Year
Gilead Sciences Inc 's Operating Income results by quarter and year
|
Select the Comparisons :
|
|
Select the Ratio:
|
Operating Income Growth Y/Y▼
|
Operating Income Growth Y/Y▼
|
| GILD Operating Income (in millions $) |
FY 2022 |
FY 2021 |
FY 2020 |
FY 2019 |
| IV Quarter |
December |
-
|
940.00
|
2,651.00
|
1,093.00
|
| III Quarter |
September |
-
|
3,842.00
|
2,001.00
|
-1,473.00
|
| II Quarter |
June |
-
|
2,246.00
|
-2,983.00
|
2,430.00
|
| I Quarter |
March |
197.00
|
2,890.00
|
2,402.00
|
2,237.00
|
| FY |
|
197.00
|
9,918.00
|
4,071.00
|
4,287.00
|
| GILD Operating Income first quarter 2022 Y/Y Growth Comment |
Gilead Sciences Inc reported drop in Operating Income in the first quarter 2022 by -93.18% to $ 197.00 millions, from the same quarter in 2021.
The fall in the first quarter 2022 Gilead Sciences Inc 's Operating Income compares unfavorably to the Company's average Operating Income jump of 41.57%.
Looking into first quarter 2022 results within Biotechnology & Pharmaceuticals industry 22 other companies have achieved higher Operating Income growth. While Gilead Sciences Inc ' s Operating Income meltdown of -93.18% ranks overall at the positon no. 1927 in the first quarter 2022.
Explain Operating Income growth
|
| GILD Operating Income ( Y/Y Growth %) |
2022
|
2021 |
2020 |
2019 |
| IV Quarter |
December |
- |
-64.54 % |
142.54 % |
-4.46 % |
| III Quarter |
September |
- |
92 % |
- |
- |
| II Quarter |
June |
- |
- |
- |
6.58 % |
| I Quarter |
March |
-93.18 % |
20.32 % |
7.38 % |
3.9 % |
| FY |
|
- |
143.63 % |
-5.04 % |
-47.72 % |
GILD Operating Income (Quarter on Quarter Growth %) |
2022
|
2021 |
2020 |
2019 |
| IV Quarter |
December |
- |
-75.53 % |
32.48 % |
- |
| III Quarter |
September |
- |
71.06 % |
- |
- |
| II Quarter |
June |
- |
-22.28 % |
- |
8.63 % |
| I Quarter |
March |
-79.04 % |
9.02 % |
119.76 % |
95.54 % |
| FY (Year on Year) |
|
- |
143.63 % |
-5.04 % |
-47.72 % |
| Operating Income Y/Y Growth Statistics |
| High |
Average |
Low |
| 2136.92 % |
41.57 % |
-48.57 % |
| (Dec. 31, 2007) |
|
(Sep 30 2019) |
|
|
| Operating Income Y/Y Growth Statistics |
| High |
Average |
Low |
| 2136.92 % |
41.57 % |
-48.57 % |
| (Dec. 31, 2007) |
|
(Sep 30 2019) |
|
| Operating Income by Quarter for the Fiscal Years 2019, 2020, 2021, 2022 |
Gilead Sciences Inc 's Q/Q Operating Income Growth
| Operating Income Q/Q Growth Statistics |
| High |
Average |
Low |
| 154.18 % |
7.84 % |
-84.25 % |
| (March 31, 2014) |
|
|
| GILD's I. Quarter Q/Q Operating Income Comment |
In the I. Quarter 2022 Gilead Sciences Inc realized fall in Operating Income sequentially by -79.04% to $ 197.00 millions, from $ 940.00 millions declared in the previous quarter.
Although cyclical influence commonly elevate I. Quarter 2022 results, this simply was not substantial to salvage Biotechnology & Pharmaceuticals's company I. Quarter 2022 achievement, Giorgi Tavares, Biotechnology & Pharmaceuticals industry advisor pointed out and continued that average quarter on quarter Operating Income growth is at 7.84% for GILD.
Within Biotechnology & Pharmaceuticals industry 17 other companies have achieved higher Operating Income quarter on quarter growth. While Gilead Sciences Inc 's Operating Income growth quarter on quarter, overall rank is 2090. |
|
|
|
| Operating Income Q/Q Growth Statistics |
| High |
Average |
Low |
| 154.18 % |
7.84 % |
-84.25 % |
| (March 31, 2014) |
|
|
| GILD's I. Quarter Q/Q Operating Income Comment |
In the I. Quarter 2022 Gilead Sciences Inc realized fall in Operating Income sequentially by -79.04% to $ 197.00 millions, from $ 940.00 millions released in the previous quarter.
Those cyclical circumstance which commonly fuel I. Quarter 2022 results, could not rescue the I. Quarter for the Gilead Sciences Inc , Giorgi Tavares, Biotechnology & Pharmaceuticals industry advisor wrote, he voiced little caution towards GILD's direction, he detected new difficulties down the road for Gilead Sciences Inc and continued that average sequential Operating Income growth is at 7.84% for Gilead Sciences Inc .
Within Biotechnology & Pharmaceuticals industry 17 other companies have achieved higher Operating Income quarter on quarter growth. While Gilead Sciences Inc 's Operating Income growth quarter on quarter, overall rank is 2090. |
|
Gilead Sciences Inc 's 12 Months Operating Income Growth Year on Year
Operating Income TTM Growth |
12 Months Ending
(Mar 31 2022) |
12 Months Ending
(Dec 31 2021) |
12 Months Ending
(Sep 30 2021) |
12 Months Ending
(Jun 30 2021) |
12 Months Ending
(Mar 31 2021) |
| Cumulative Operating Income 12 Months Ending |
$ 7,225.00 |
$ 9,918.00 |
$ 11,629.00 |
$ 9,788.00 |
$ 4,559.00 |
| Y / Y Operating Income Growth (TTM) |
58.48 % |
143.63 % |
362.75 % |
- |
2.4 % |
| Year on Year Operating Income Growth Overall
Ranking |
# 527 |
# 375 |
# 88 |
# 0 |
# 1191 |
| Seqeuential Operating Income Change (TTM) |
-27.15 % |
-14.71 % |
18.81 % |
114.7 % |
11.99 % |
| Seq. Operating Income Growth (TTM) Overall
Ranking |
# 1927 |
# 1472 |
# 340 |
# 98 |
# 679 |
| Cumulative Operating Income growth
Comment |
With the quarterly Operating Income reported in the Mar 31 2022 period, Gilead Sciences Inc 's cumulative twelve months Operating Income were $ 7,225 millions, company would post below average annual Operating Income growth of 11.99% year on year, if the fiscal year would end at Mar 31 2022.
A slow-down in the Gilead Sciences Inc 's Operating Income growth from the 940% growth in Dec 31 2021.
In the Healthcare sector 38 other companies have achieved higher trailing twelve month Operating Income growth. While Operating Income growth total ranking has deteriorated compare to previous quarter from 375 to 527. |
| Operating Income TTM Q/Q Growth Statistics |
| High |
Average |
Low |
2136.92 % |
41.57 % |
-48.57 % |
|
|
|
|
|
| Operating Income TTM Y/Y Growth Statistics |
| High |
Average |
Low |
2464.91 % |
69.66 % |
-91.63 % |
|
|
|
| Operating Income TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 23 |
| Sector |
# 148 |
| S&P 500 |
# 1927 |
|
| Cumulative Operating Income growth
Comment |
With the quarterly Operating Income reported in the Mar 31 2022 period, Gilead Sciences Inc 's cumulative twelve months Operating Income were $ 7,225 millions, company would post below average annual Operating Income growth of -91.63% year on year, if the fiscal year would end at Mar 31 2022.
A slow-down in the Gilead Sciences Inc 's Operating Income growth from the 940% growth in Dec 31 2021.
In the Healthcare sector 38 other companies have achieved higher trailing twelve month Operating Income growth. While Operating Income growth total ranking has deteriorated compare to previous quarter from 375 to 527. |
| Operating Income TTM Q/Q Growth Statistics |
| High |
Average |
Low |
2136.92 % |
41.57 % |
-48.57 % |
|
|
|
| Operating Income TTM Y/Y Growth Statistics |
| High |
Average |
Low |
2464.91 % |
69.66 % |
-91.63 % |
|
|
|
| Operating Income TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 23 |
| Sector |
# 148 |
| S&P 500 |
# 1927 |
|
